EP4436603A1 - Traitement d'une maladie démyélinisante du système nerveux central (snc) avec du satralizumab - Google Patents

Traitement d'une maladie démyélinisante du système nerveux central (snc) avec du satralizumab

Info

Publication number
EP4436603A1
EP4436603A1 EP22898636.0A EP22898636A EP4436603A1 EP 4436603 A1 EP4436603 A1 EP 4436603A1 EP 22898636 A EP22898636 A EP 22898636A EP 4436603 A1 EP4436603 A1 EP 4436603A1
Authority
EP
European Patent Office
Prior art keywords
subject
antibody
satralizumab
demyelination
compatible
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22898636.0A
Other languages
German (de)
English (en)
Other versions
EP4436603A4 (fr
Inventor
Takatoshi Ozawa
Mai Yamashiro
Hajime Ito
Shunsuke Yoshida
Jillian SMITH
Ivana Vodopivec
Sian LENNON-CHRIMES
Gaelle KLINGELSCHMITT
Hans-Christian VON BUEDINGEN
Hanna SILBER BAUMANN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Original Assignee
F Hoffmann La Roche AG
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2021/043459 external-priority patent/WO2023095305A1/fr
Priority claimed from PCT/JP2021/048257 external-priority patent/WO2023119638A1/fr
Application filed by F Hoffmann La Roche AG, Chugai Pharmaceutical Co Ltd filed Critical F Hoffmann La Roche AG
Publication of EP4436603A1 publication Critical patent/EP4436603A1/fr
Publication of EP4436603A4 publication Critical patent/EP4436603A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Definitions

  • the present invention relates to a medicament or a pharmaceutical composition for treatment, or for reducing the risk of relapse, of a demyelinating disease of the central nervous system (CNS) that is characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody, the composition comprising an anti-IL-6 receptor antibody or antigen binding fragment thereof.
  • CNS central nervous system
  • MOG anti-myelin oligodendrocyte glycoprotein
  • the present invention also relates to a method of treatment, or of reducing the risk of relapse, of said demyelinating disease by administering an anti-IL-6 receptor antibody or antigen binding fragment thereof to a subject in need thereof.
  • Myelin oligodendrocyte glycoprotein antibody-associated disease is a rare autoimmune demyelinating disease of the CNS characterized by the presence of anti-myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in adults and children.
  • MOG is a transmembrane protein expressed on oligodendrocytes and the outer layers of myelin sheath [NPL 19]. The disease is characterized by attacks of optic neuritis, transverse myelitis, brain or brainstem inflammation, or combinations thereof (NPL 1). A combination of a compatible clinical and radiologic phenotype and seropositivity for MOG-IgG is required to establish the diagnosis.
  • MOGAD is worsened by several multiple sclerosis (MS) disease-modifying treatments, including interferon-beta (IFN-beta), glatiramer acetate, teriflunomide, dimethyl fumarate, cladribine, fingolimod, natalizumab, and alemtuzumab (NPL 7, NPL 8, NPL 9, and NPL 6).
  • IFN-beta interferon-beta
  • glatiramer acetate glatiramer acetate
  • teriflunomide dimethyl fumarate
  • cladribine cladribine
  • fingolimod natalizumab
  • alemtuzumab alemtuzumab
  • the current MOGAD treatment paradigm includes the use of corticosteroids with or without intravenous immunoglobulins (IVIg) or plasma exchange (PLEX) for acute treatment of attacks, and empirically selected conventional steroid-sparing immunosuppressant treatments (ISTs) and rituximab (RTX) for relapse prevention (NPL 10, NPL 9, NPL 11, NPL 12, and NPL 13).
  • IVIG intravenous immunoglobulins
  • PLEX plasma exchange
  • RTX rituximab
  • Humanized antibodies like tocilizumab are first-generation antibody drugs.
  • second-generation antibody drugs By improving first-generation antibody drugs, second-generation antibody drugs with improved efficacy, convenience, and cost are being developed (PTL 2 and PTL 3).
  • SA237 satralizumab
  • SA237 is a novel anti-IL-6 receptor antibody to which improvement technologies such as enhancement of antigen-binding ability, pharmacokinetics, and stability, and reduction of immunogenicity risk, have been applied (PTL 3 and PTL 4).
  • Satralizumab is a humanized anti-IL-6 receptor monoclonal antibody with pH-dependent antigen binding. It specifically targets the human IL-6 receptor (IL-6R) and suppresses IL-6 signaling by inhibiting the binding of IL-6 to membrane-bound IL-6R and soluble IL-6R.
  • IL-6R human IL-6 receptor
  • Satralizumab was constructed by modifying the amino acid sequence of tocilizumab to prolong its plasma half-life. Satralizumab also shows a decreased antibody molecule isoelectric point and stronger binding to FcRn compared to tocilizumab. Moreover, its Fc region has been modified to minimize the antibody-dependent cellular cytotoxicity and complement-dependent cytotoxic effector activity compared to tocilizumab.
  • Prior-art literature information related to the invention of the present application is shown below.
  • NPL 8 Wynford-Thomas R, Jacob A, et al. Neurological update: MOG antibody disease. J Neurol. 2019;266(5):1280-1286.
  • NPL 9 Chen JJ, Flanagan EP, Bhatti MT, et al. Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. Neurology. 2020;95(2):e111-e120.
  • NPL 10 Stiebel-Kalish H, Hellmann MA, Mimouni M, et al. Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e572.
  • NPL 11 Chen JJ and Bhatti MT. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis. Curr Opin Neurol. 2020;33(1):47-54.
  • NPL 12 Hegen H, Reindl M. Recent developments in MOG-IgG associated neurological disorders. Ther Adv Neurol Disord. 2020;13:1756286420945135.
  • NPL 13 Whittam DH, Karthenseyan V, Gibbons E, et al. Treatment of MOG antibody associated disorders: results of an international survey. J Neurol. 2020a;267(12):3565-3577.
  • the IL-6 inhibitor is an anti-IL-6 antibody or antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or antigen binding fragment thereof.
  • A1.3 The medicament of A1.1 or A1.2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof.
  • A1.4 The medicament of any one of A1.1-A1.3, wherein the IL-6 inhibitor is a humanized antibody.
  • IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
  • VH heavy chain variable region
  • VH CDR1 comprising the amino acid sequence of SEQ ID NO: 5
  • VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6
  • VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7
  • VL light chain variable region
  • A1.6 The medicament of A1.5, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2.
  • the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4.
  • A1.8 The medicament of any one of A1.5-A1.7, wherein the IL-6 inhibitor is satralizumab.
  • A1.9 The medicament of any one of A1.1-A1.8, for delaying relapse of, reducing frequency of relapse of, or reducing severity of relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody.
  • A1.10 The medicament of any one of A1.1-A1.9, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD and multiple sclerosis (MS).
  • AQP4 anti-aquaporin-4
  • A1.11 The medicament of any one of A1.1-A1.10, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD, multiple sclerosis (MS) and anti-NMDAR autoimmune encephalitis.
  • A1.12 The medicament of any one of A1.1-A1.11, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • A1.13 The medicament of A1.12, wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay, and (ii) 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination.
  • ADAM acute disseminated encephalomyelitis
  • A1.14 The medicament of any one of A1.1-A1.13, wherein (i) the subject is determined to be MOG-IgG-seropositive by a cell-based assay, and (ii) the subject has experienced 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis, brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination.
  • optic neuritis ON
  • TM transverse myelitis
  • encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis, brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain
  • A1.15 The medicament of any one of A1.1-A1.14, wherein the subject is anti-aquaporin-4 (AQP4) antibody-negative.
  • A1.16 The medicament of any one of A1.1-A1.15, wherein the subject is aged 12 years or older.
  • A1.17 The medicament of any one of A1.1-A1.16, wherein the subject is receiving no ongoing chronic immunosuppressive therapy.
  • A1.18 The medicament of any one of A1.1-A1.16, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroid (OCS), or a combination of AZA or MMF and OCS.
  • AZA azathioprine
  • MMF mycophenolate mofetil
  • OCS oral corticosteroid
  • A1.21 The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration.
  • A1.22 The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration.
  • A1.23 The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration.
  • A1.24 The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration.
  • A1.25 The medicament of any one of A1.5-A1.18, which is characterized in that the medicament is used such that 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration.
  • A1.26 The medicament of any one of A1.5-A1.25, which is characterized in that the medicament is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject subcutaneously.
  • A1.27 The medicament of any one of A1.5-A1.26, which is characterized in that the medicament is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • A1.33 The medicament of any one of A1.1-A1.32, which increases the subject's high-contrast best corrected visual acuity (BCVA), or low-contrast visual acuity (LCVA), National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) composite score or subscale scores, EuroQol EQ-5D-5L score, or SF-36v2 Health Survey (SF-36v2) score; or reduces the subject's Expanded Disability Status Scale (EDSS) score, Functional System Scores (FSSs) of the EDSS, Short-Form McGill Pain Questionnaire (SF-MPQ-2) score, or MOG-IgG titers.
  • BCVA high-contrast best corrected visual acuity
  • LCVA Low-contrast visual acuity
  • NKI VFQ-25 National Eye Institute Visual Functioning Questionnaire-25
  • FSSs Functional System Scores
  • SF-MPQ-2 Short-Form McGill Pain Questionnaire
  • the IL-6 inhibitor is an anti-IL-6 antibody or antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or antigen binding fragment thereof.
  • A2.3 The pharmaceutical composition of A2.1 or A2.2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof.
  • A2.4 The pharmaceutical composition of any one of A2.1-A2.3, wherein the IL-6 inhibitor is a humanized antibody.
  • IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
  • VH heavy chain variable region
  • VH CDR1 comprising the amino acid sequence of SEQ ID NO: 5
  • VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6
  • VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7
  • VL light chain variable region
  • A2.6 The pharmaceutical composition of A2.5, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2.
  • the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4.
  • A2.8 The pharmaceutical composition of any one of A2.5-A2.7, wherein the IL-6 inhibitor is satralizumab.
  • A2.9 The pharmaceutical composition of any one of A2.1-A2.8, for delaying relapse of, reducing frequency of relapse of, or reducing severity of relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody.
  • A2.10 The pharmaceutical composition of any one of A2.1-A2.9, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD and multiple sclerosis (MS).
  • AQP4 anti-aquaporin-4
  • A2.11 The pharmaceutical composition of any one of A2.1-A2.10, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD, multiple sclerosis (MS) and anti-NMDAR autoimmune encephalitis.
  • A2.12 The pharmaceutical composition of any one of A2.1-A2.11, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • A2.13 The pharmaceutical composition of A2.12, wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay, and (ii) 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis, brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination.
  • ADAM acute disseminated encephalomyelitis
  • A2.15 The pharmaceutical composition of any one of A2.1-A2.14, wherein the subject is anti-aquaporin-4 (AQP4) antibody-negative.
  • A2.16 The pharmaceutical composition of any one of A2.1-A2.15, wherein the subject is aged 12 years or older.
  • A2.17 The pharmaceutical composition of any one of A2.1-A2.16, wherein the subject is receiving no ongoing chronic immunosuppressive therapy.
  • A2.18 The pharmaceutical composition of any one of A2.1-A2.16, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroid (OCS), or a combination of AZA or MMF and OCS.
  • AZA azathioprine
  • MMF mycophenolate mofetil
  • OCS oral corticosteroid
  • A2.25 The pharmaceutical composition of any one of A2.5-A2.18, which is characterized in that the pharmaceutical composition is used such that 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration.
  • A2.26 The pharmaceutical composition of any one of A2.5-A2.25, which is characterized in that the pharmaceutical composition is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject subcutaneously.
  • A2.27 The pharmaceutical composition of any one of A2.5-A2.26, which is characterized in that the pharmaceutical composition is used such that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • A2.28 The pharmaceutical composition of any one of A2.1-A2.27, which is characterized in that the pharmaceutical composition is used in combination with an immunosuppressive therapy (IST).
  • IST immunosuppressive therapy
  • A2.29 The pharmaceutical composition of A2.28, wherein the IST is a therapy with one or more immunosuppressive agents selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF) and oral corticosteroid (OCS).
  • A2.30 The pharmaceutical composition of A2.29, wherein the immunosuppressive agent comprises prednisone or prednisolone.
  • A2.31 The pharmaceutical composition of any one of A2.1-A2.30, which delays the time from an administration of the IL-6 inhibitor to the first occurrence of a relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody.
  • A2.32 The pharmaceutical composition of A2.31, which reduces one or more of the followings: (a) the rate of relapses of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody; (b) the rate of active lesions on MRI of the neuroaxis; (c) the proportion of subjects receiving rescue therapy; or (d) the rate of inpatient hospitalizations.
  • A2.33 The pharmaceutical composition of any one of A2.1-A2.32, which increases the subject's high-contrast best corrected visual acuity (BCVA), or low-contrast visual acuity (LCVA), National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) composite score or subscale scores, EuroQol EQ-5D-5L score, or SF-36v2 Health Survey (SF-36v2) score; or reduces the subject's Expanded Disability Status Scale (EDSS) score, Functional System Scores (FSSs) of the EDSS, Short-Form McGill Pain Questionnaire (SF-MPQ-2) score or MOG-IgG titers.
  • BCVA high-contrast best corrected visual acuity
  • LCVA National Eye Institute Visual Functioning Questionnaire-25
  • FESs Functional System Scores
  • SF-MPQ-2 Short-Form McGill Pain Questionnaire
  • IL-6 inhibitor in the preparation of a medicament for treating demyelinating disease of the central nervous system (CNS) characterized by the presence of an anti-myelin oligodendrocyte glycoprotein (MOG) antibody or for reducing risk of relapse in a relapsing demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody in a subject who is anti-MOG antibody-positive.
  • CNS central nervous system
  • MOG anti-myelin oligodendrocyte glycoprotein
  • B2 The use of B1, wherein the IL-6 inhibitor is an anti-IL-6 antibody or antigen-binding fragment thereof, or an anti-IL-6 receptor antibody or antigen binding fragment thereof.
  • B3 The use of B1 or B2, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof.
  • B4 The use of any one of B1-B3, wherein the IL-6 inhibitor is a humanized antibody.
  • B5 The use of any one of B1-B4, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody or antigen binding fragment thereof comprising a heavy chain variable region (VH) CDR1 comprising the amino acid sequence of SEQ ID NO: 5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10.
  • VH heavy chain variable region
  • B6 The use of B5, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2.
  • B7 The use of B5 or B6, wherein the IL-6 inhibitor is an anti-IL-6 receptor antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 3 and a light chain comprising the amino acid sequence of SEQ ID NO: 4.
  • B8 The use of any one of B5-B7, wherein the IL-6 inhibitor is satralizumab.
  • B11 The use of any one of B1-B10, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD, multiple sclerosis (MS) and anti-NMDAR autoimmune encephalitis.
  • B12 The use of any one of B1-B11, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • B12 wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay, and (ii) 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination.
  • ADAM acute disseminated encephalomyelitis
  • B14 The use of any one of B1-B13, wherein (i) the subject is determined to be MOG-IgG-seropositive by a cell-based assay, and (ii) the subject has experienced 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination.
  • optic neuritis ON
  • TM transverse myelitis
  • encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome
  • [B15] The use of any one of B1-B14, wherein the subject is anti-aquaporin-4 (AQP4) antibody-negative.
  • [B16] The use of any one of B1-B15, wherein the subject is aged 12 years or older.
  • [B17] The use of any one of B1-B16, wherein the subject is receiving no ongoing chronic immunosuppressive therapy.
  • [B18] The use of any one of B1-B16, wherein the subject is receiving ongoing treatment with a stable dose of azathioprine (AZA), mycophenolate mofetil (MMF), oral corticosteroid (OCS), or a combination of AZA or MMF and OCS.
  • AZA azathioprine
  • MMF mycophenolate mofetil
  • OCS oral corticosteroid
  • any one of B5-B18 wherein the medicament is characterized in that the medicament is used such that 60 mg or 120 mg, 120 mg or 180 mg, and 180 mg or 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg, between 40 and 100 kg, and over 100 kg respectively for each administration.
  • the medicament is used such that 60 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration.
  • any one of B5-B18 which is characterized in that the medicament is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration.
  • the medicament is used such that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration.
  • any one of B5-B18 which is characterized in that the medicament is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration.
  • the medicament is used such that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration.
  • the medicament is used such that 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration.
  • B29 The use of B28, wherein the IST is a therapy with one or more immunosuppressive agents selected from the group consisting of azathioprine (AZA), mycophenolate mofetil (MMF), and oral corticosteroid (OCS).
  • AZA azathioprine
  • MMF mycophenolate mofetil
  • OCS oral corticosteroid
  • B30 The use of B29, wherein the immunosuppressive agent comprises prednisone or prednisolone.
  • B31 The use of any one of B1-B30, wherein the medicament delays the time from an administration of the IL-6 inhibitor to the first occurrence of a relapse of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody.
  • B31 The use of B31, wherein the medicament reduces one or more of the followings: (a) the rate of relapses of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody; (b) the rate of active lesions on MRI of the neuroaxis; (c) the proportion of subjects receiving rescue therapy; or (d) the rate of inpatient hospitalizations.
  • B33 The use of any one of B1-B32, wherein the medicament increases the subject's high-contrast best corrected visual acuity (BCVA), or low-contrast visual acuity (LCVA), National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) composite score or subscale scores, EuroQol EQ-5D-5L score, or SF-36v2 Health Survey (SF-36v2) score; or reduces the subject's Expanded Disability Status Scale (EDSS) score, Functional System Scores (FSSs) of the EDSS, Short-Form McGill Pain Questionnaire (SF-MPQ-2) score or MOG-IgG titers.
  • BCVA high-contrast best corrected visual acuity
  • LCVA National Eye Institute Visual Functioning Questionnaire-25
  • FESs Functional System Scores
  • SF-MPQ-2 Short-Form McGill Pain Questionnaire
  • MOG-IgG titers MOG-IgG titers.
  • CNS central nervous system
  • MOG anti-myelin oligodendrocyte glycoprotein
  • VH heavy chain variable region
  • VH CDR1 comprising the amino acid sequence of SEQ ID NO: 5
  • VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6
  • VH CDR3 comprising the amino acid sequence of SEQ ID NO: 7
  • VL light chain variable region
  • the IL-6 inhibitor for use of C5, wherein the anti-IL-6 receptor antibody or antigen binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO: 1 and a VL comprising the amino acid sequence of SEQ ID NO: 2.
  • the IL-6 inhibitor for use of any one of C1-C9, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD and multiple sclerosis (MS).
  • the IL-6 inhibitor for use of any one of C1-C10, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is a disease other than anti-aquaporin-4 (AQP4) antibody-positive NMOSD, multiple sclerosis (MS) and anti-NMDAR autoimmune encephalitis.
  • the IL-6 inhibitor for use of any one of C1-C11, wherein the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody is myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
  • IL-6 inhibitor for use of C12, wherein the MOGAD is characterized by (i) serum positivity for MOG-IgG by a cell-based assay, and (ii) 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis, brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination.
  • ADAM acute disseminated encephalomyelitis
  • IL-6 inhibitor for use of any one of C1-C13, wherein (i) the subject is determined to be MOG-IgG-seropositive by a cell-based assay, and (ii) the subject has experienced 2 or more attacks of any one or more of: optic neuritis (ON); transverse myelitis (TM); or encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and brain syndrome compatible with demyelination.
  • optic neuritis ON
  • TM transverse myelitis
  • encephalitis selected from the group consisting of acute disseminated encephalomyelitis (ADEM), brainstem encephalitis, cortical encephalitis; brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, and
  • AZA azathioprine
  • MMF mycophenolate mofetil
  • OCS oral corticosteroid
  • the IL-6 inhibitor for use of any one of C5-C18 which is characterized in that 60 mg or 120 mg, 120 mg or 180 mg, and 180 mg or 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg, between 40 and 100 kg, and over 100 kg respectively for each administration.
  • the IL-6 inhibitor for use of any one of C5-C18 which is characterized in that 60 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration.
  • the IL-6 inhibitor for use of any one of C5-C18 which is characterized in that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of less than 40 kg for each administration.
  • the IL-6 inhibitor for use of any one of C5-C18 which is characterized in that 120 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration.
  • the IL-6 inhibitor for use of any one of C5-C18 which is characterized in that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of between 40 and 100 kg for each administration.
  • the IL-6 inhibitor for use of any one of C5-C18 which is characterized in that 180 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration.
  • the IL-6 inhibitor for use of any one of C5-C18 which is characterized in that 240 mg of the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered subcutaneously to the subject with body weight of over 100 kg for each administration.
  • the IL-6 inhibitor for use of any one of C5-C25 which is characterized in that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject subcutaneously.
  • the IL-6 inhibitor for use of any one of C5-C26 which is characterized in that the anti-IL-6 receptor antibody or antigen binding fragment thereof is administered to the subject every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • the IL-6 inhibitor for use of any one of C1-C27 which is used in combination with an immunosuppressive therapy (IST).
  • IST immunosuppressive therapy
  • C32 The IL-6 inhibitor for use of C31, which reduces one or more of the followings: (a) the rate of relapses of the demyelinating disease of the CNS characterized by the presence of an anti-MOG antibody; (b) the rate of active lesions on MRI of the neuroaxis; (c) the proportion of subjects receiving rescue therapy; or (d) the rate of inpatient hospitalizations.
  • C33 The IL-6 inhibitor for use of any one of C1-C32, which increases the subject's high-contrast best corrected visual acuity (BCVA), or low-contrast visual acuity (LCVA), National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25) composite score or subscale scores, EuroQol EQ-5D-5L score, or SF-36v2 Health Survey (SF-36v2) score; or reduces the subject's Expanded Disability Status Scale (EDSS) score, Functional System Scores (FSSs) of the EDSS, Short-Form McGill Pain Questionnaire (SF-MPQ-2) score or MOG-IgG titers.
  • BCVA high-contrast best corrected visual acuity
  • LCVA Low-contrast visual acuity
  • NKI VFQ-25 National Eye Institute Visual Functioning Questionnaire-25
  • FSSs Functional System Scores
  • SF-MPQ-2 Short-Form McGill Pain Questionnaire
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination.
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • ON optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • optic neuritis ON
  • brainstem syndrome compatible with demyelination cerebellar syndrome compatible with demyelination
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • ON optic neuritis
  • TM transverse myelitis
  • brainstem syndrome compatible with demyelination cerebellar syndrome compatible with demyelination
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4 antibody-negative
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • OPD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • OAM optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • O optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination cerebellar syndrome compatible with demyelination
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • ONP4 myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • OAM optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of less than 40 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of less than 40 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of less than 40 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of less than 40 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • Q4W body weight of less than 40 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADM acute disseminated encephalomyelitis
  • Q2W body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Q2W optical neuritis
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of over 100 kg every two weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Q2W transverse myelitis
  • Q4W cerebellar syndrome compatible with demyelination
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • satralizumab is used in combination with azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • OUA optic neuritis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • ON optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • satralizumab is used in combination with azathioprine (AZA).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • ON optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • OZA optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • satralizumab is used in combination with azathioprine (AZA).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4 antibody-negative
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • OZA optic neuritis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • OZA optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • TM transverse myelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • O optic neuritis
  • TM transverse myelitis
  • TM transverse myelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • OZA optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • satralizumab
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • TM transverse myelitis
  • 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 60 mg of satralizumab for each administration is administered subcutaneous
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • OZA optic neuritis
  • Q2W body weight
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomye
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • satralizumab
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • ON optic neuritis
  • 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W)
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 120 mg of satralizumab for each administration is administered subcutaneous
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomye
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • satralizumab for each administration is
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • ON optic neuritis
  • 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • TM transverse myelitis
  • 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 120 mg of satralizumab for each administration is administered sub
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomy
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathio
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • satralizumab for each administration is
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • ON optic neuritis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered sub
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomy
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • OZA optic neuritis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • ON optic neuritis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W)
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the subject
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4 antibody-negative
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated ence
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • ON optic neuritis
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein sa
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • satralizumab for each administration is administered subcutaneously to the
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 240 mg of satralizumab for each administration is administered sub
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • TM transverse myelitis
  • DAM acute disseminated encephalomye
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with azathioprine (AZA).
  • AZA azathioprine
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • satralizumab is used in combination with mycophenolate mofetil (MMF).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • O optic neuritis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • O optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • ON optic neuritis
  • TM transverse myelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • O optic neuritis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • ON optic neuritis
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4 antibody-negative
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • satralizumab is used in combination with mycophenolate mofetil (MMF).
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 60 mg of satralizumab for each administration is administered sub
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomy
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 120 mg of satralizumab for each administration is administered sub
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomy
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalo
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenol
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalo
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 180 mg of satralizumab for each administration is administered subcutaneous
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomye
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mo
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein s
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • DAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • 240 mg of satralizumab for each administration is administered
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADM acute disseminated
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • TM transverse myelitis
  • DAM acute disseminated encephalomy
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with mycophenolate mofetil (MMF).
  • MMF mycophenolate mofetil
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W for three times, and thereafter every four weeks
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomye
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W for three times, and thereafter every four weeks
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomye
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W every four weeks
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomy
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W every four weeks
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomy
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W every four weeks
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 180 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • Q2W body weight of over 100 kg every two weeks
  • Q4W three times, and thereafter every four weeks
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • TM transverse myelitis
  • DAM acute disseminated encephalomye
  • Satralizumab for use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 240 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of over 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W); and wherein satralizumab is used in combination with oral corticosteroid (OCS).
  • OCS oral corticosteroid
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON).
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM).
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • O optic neuritis
  • ON brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • OAM optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • O optic neuritis
  • TM transverse myelitis
  • brainstem syndrome compatible with demyelination a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease
  • cerebellar syndrome compatible with demyelination.
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • O optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • optic neuritis ON
  • brainstem syndrome compatible with demyelination cerebellar syndrome compatible with demyelination
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • optic neuritis ON
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-aquaporin-4
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • O optic neuritis
  • ON optic neuritis
  • brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination.
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • O optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination.
  • O optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination cerebellar syndrome compatible with demyelination
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • ONP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • optic neuritis ON
  • brainstem syndrome compatible with demyelination cerebellar syndrome compatible with demyelination
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination.
  • OAM optic neuritis
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM optic neuritis
  • DAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination and wherein 60 mg of satralizuma
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W 60 mg of satralizumab for each administration is administered subcutaneous
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ODM optic neuritis
  • Q2W body weight
  • Q4W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 60 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight of less than 40 kg every two weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM optic neuritis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ON optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W body weight of less than 40 kg every two weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of less than 40 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • ODM optic neuritis
  • Q2W body weight
  • Q4W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of less than 40 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ON optic neuritis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of acute disseminated encephalomyelitis (ADEM) and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON) and transverse myelitis (TM); and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • TM transverse myelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM optic neuritis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • Q2W body weight of between 40 and 100 kg every two weeks
  • Q4W every four weeks
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Q2W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, and cerebellar syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • TM transverse myelitis
  • TM brainstem syndrome compatible with demyelination
  • cerebellar syndrome compatible with demyelination
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • O optic neuritis
  • TM transverse myelitis
  • ADAM acute disseminated encephalomyelitis
  • Q4W body weight
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • OAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • TM transverse myelitis
  • DAM acute disseminated encephalomyelitis
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive, and has experienced 2 or more attacks of one or more selected from the group consisting of optic neuritis (ON), transverse myelitis (TM), brainstem syndrome compatible with demyelination, cerebellar syndrome compatible with demyelination, acute disseminated encephalomyelitis (ADEM), and other brain syndrome compatible with demyelination; and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • Satralizumab for use in reducing risk of relapse in a relapsing myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) in a subject, wherein the subject is anti-MOG antibody-positive and anti-aquaporin-4 (AQP4) antibody-negative, and has experienced 2 or more attacks of optic neuritis (ON) and wherein 120 mg of satralizumab for each administration is administered subcutaneously to the subject with body weight of between 40 and 100 kg every two weeks (Q2W) for three times, and thereafter every four weeks (Q4W).
  • MOGAD myelin oligodendrocyte glycoprotein antibody-associated disease
  • AQP4 anti-MOG antibody-positive and anti-aquaporin-4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un moyen pour traiter une maladie démyélinisante du système nerveux central (SNC) caractérisée par la présence d'un anticorps dirigé contre la glycoprotéine de la myéline oligodendrocytaire (MOG, « myelin oligodendrocyte glycoprotein »), ainsi que pour réduire le risque de rechute dans la maladie démyélinisante, comprenant un anticorps anti-récepteur d'IL-6 ou un fragment de liaison à l'antigène de celui-ci.
EP22898636.0A 2021-11-26 2022-11-25 Traitement d'une maladie démyélinisante du système nerveux central (snc) avec du satralizumab Pending EP4436603A4 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
PCT/JP2021/043459 WO2023095305A1 (fr) 2021-11-26 2021-11-26 Traitement d'une maladie démyélinisante du système nerveux central (snc) à l'aide de satralizumab
PCT/JP2021/048257 WO2023119638A1 (fr) 2021-12-24 2021-12-24 Traitement d'une maladie démyélinisante du système nerveux central (snc) par du satralizumab
PCT/JP2022/039605 WO2023095510A1 (fr) 2021-11-26 2022-10-25 Traitement d'une maladie démyélinisante du système nerveux central (snc) par du satralizumab
PCT/JP2022/043453 WO2023095854A1 (fr) 2021-11-26 2022-11-25 Traitement d'une maladie démyélinisante du système nerveux central (snc) avec du satralizumab

Publications (2)

Publication Number Publication Date
EP4436603A1 true EP4436603A1 (fr) 2024-10-02
EP4436603A4 EP4436603A4 (fr) 2026-04-08

Family

ID=86539582

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22898636.0A Pending EP4436603A4 (fr) 2021-11-26 2022-11-25 Traitement d'une maladie démyélinisante du système nerveux central (snc) avec du satralizumab

Country Status (2)

Country Link
EP (1) EP4436603A4 (fr)
WO (1) WO2023095854A1 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CA2972393A1 (fr) * 2015-02-27 2016-09-01 Chugai Seiyaku Kabushiki Kaisha Composition pour le traitement de maladies associees a il-6

Also Published As

Publication number Publication date
WO2023095854A1 (fr) 2023-06-01
EP4436603A4 (fr) 2026-04-08

Similar Documents

Publication Publication Date Title
WO2023095852A1 (fr) Traitement d'une maladie démyélinisante du système nerveux central (snc) avec du satralizumab
WO2023140269A1 (fr) Traitement de l'encéphalite auto-immune avec le satralizumab
US20240301072A1 (en) Methods for the treatment of thyroid eye disease
Zeng et al. Clinical characteristics and long-term follow-up outcomes of myelin oligodendrocyte glycoprotein antibody-associated disease in Han Chinese participants
JP2024069373A (ja) 視神経脊髄炎の処置のためのエクリズマブ
CN121152807A (zh) 使用抗cd40l抗体治疗多发性硬化症
US20230322942A1 (en) Methods for treating multiple sclerosis with ocrelizumab
CA3251727A1 (fr) Compositions et procédés pour le traitement d'un trouble du spectre de la neuromyélite optique
WO2023095854A1 (fr) Traitement d'une maladie démyélinisante du système nerveux central (snc) avec du satralizumab
Jacob et al. Myasthenia gravis and other neuromuscular junction disorders
WO2023119638A1 (fr) Traitement d'une maladie démyélinisante du système nerveux central (snc) par du satralizumab
US20250011417A1 (en) Methods for the treatment of thyroid eye disease
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
Agrawal et al. Neuromyelitis optica spectrum disorder with negative aquaporin-4 antibodies and positive anti-myelin oligodendrocyte glycoprotein antibodies: a case report
KR20260022396A (ko) 항-Aβ 프로토피브릴 항체를 사용한 치료 방법
WO2024225417A1 (fr) Traitement d'une maladie oculaire thyroïdienne par satralizumab
WO2025106642A1 (fr) Méthodes de traitement d'une maladie de l'œil liée à la thyroïde
Dai et al. Case Report: Papillophlebitis associated with MOG-IgG-associated optic neuritis
HK40110527A (zh) 伊奈利珠单抗及其在治疗或预防igg4相关疾病中的使用方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20251022BHEP

Ipc: A61K 31/52 20060101ALI20251022BHEP

Ipc: A61K 31/5377 20060101ALI20251022BHEP

Ipc: A61K 31/573 20060101ALI20251022BHEP

Ipc: A61P 25/00 20060101ALI20251022BHEP

Ipc: A61P 37/06 20060101ALI20251022BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20260309

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20260303BHEP

Ipc: A61K 31/52 20060101ALI20260303BHEP

Ipc: A61K 31/5377 20060101ALI20260303BHEP

Ipc: A61K 31/573 20060101ALI20260303BHEP

Ipc: A61P 25/00 20060101ALI20260303BHEP

Ipc: A61P 37/06 20060101ALI20260303BHEP